norfloxacin has been researched along with Cross Infection in 24 studies
Norfloxacin: A synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE.
norfloxacin : A quinolinemonocarboxylic acid with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase.
Cross Infection: Any infection which a patient contracts in a health-care institution.
| Excerpt | Relevance | Reference |
|---|---|---|
| "One hundred thirty-eight patients with pyelonephritis were treated with norfloxacin, 400 mg twice daily." | 9.06 | Review of the efficacy of oral norfloxacin in pyelonephritis and nosocomial urinary tract infection. ( Corrado, ML; Lancaster, MS; Roylance, PJ; Struble, WE, 1990) |
| "We performed a 5-year retrospective study to evaluate the effect of long-term administration of norfloxacin on the epidemiology of severe hospital-acquired infections in patients with advanced cirrhosis." | 5.30 | Epidemiology of severe hospital-acquired infections in patients with liver cirrhosis: effect of long-term administration of norfloxacin. ( Campillo, B; Dupeyron, C; Leluan, G; Mangeney, N; Richardet, JP, 1998) |
| "One hundred thirty-eight patients with pyelonephritis were treated with norfloxacin, 400 mg twice daily." | 5.06 | Review of the efficacy of oral norfloxacin in pyelonephritis and nosocomial urinary tract infection. ( Corrado, ML; Lancaster, MS; Roylance, PJ; Struble, WE, 1990) |
| "In a multiclinic, randomized trial, oral norfloxacin, a fluoroquinolone antibacterial, was compared with several standard parenteral regimens for the treatment of nonbacteremic, hospital-acquired urinary tract infections." | 5.06 | Oral norfloxacin versus parenteral treatment of nosocomial urinary tract infection. ( Cox, CE; Grad, C; McCabe, RE, 1987) |
| "The effect of once daily doses of 200 mg oral norfloxacin on the occurrence of catheter-associated bacteriuria (greater than 1000 CFU/ml) and pyuria was studied in 105 post-operative gynaecologic patients." | 3.67 | Postoperative prophylaxis with norfloxacin in patients requiring bladder catheters. ( Andriesse, R; Hamersma, K; Mintjes-de Groot, AJ; van Dijk, A; Verbrugh, HA, 1988) |
| "We performed a 5-year retrospective study to evaluate the effect of long-term administration of norfloxacin on the epidemiology of severe hospital-acquired infections in patients with advanced cirrhosis." | 1.30 | Epidemiology of severe hospital-acquired infections in patients with liver cirrhosis: effect of long-term administration of norfloxacin. ( Campillo, B; Dupeyron, C; Leluan, G; Mangeney, N; Richardet, JP, 1998) |
| "Treatment with norfloxacin induced the development of quinolone-resistant E." | 1.30 | Development of quinolone-resistant strains of Escherichia coli in stools of patients with cirrhosis undergoing norfloxacin prophylaxis: clinical consequences. ( Aparicio, JR; Arroyo, A; Carnicer, F; de Vera, F; Girona, E; Gutiérrez, A; Palazón, JM; Pascual, S; Pérez-Mateo, M; Plazas, J; Such, J, 1999) |
| "This study analyzes hospital acquired bacterial infections in cirrhotic patients with ascites and low levels of total protein in ascitic fluid (n = 53) and cirrhotic patients with gastrointestinal hemorrhage (n = 26), both submitted to selective intestinal decontamination with norfloxacin during the hospitalization." | 1.28 | [An analysis of hospital bacterial infections in cirrhotic patients undergoing selective intestinal decontamination]. ( Balanzó, J; Fábrega, E; Guarner, C; Méndez, C; Soriano, G; Such, J; Teixidó, M; Tena, F; Tomás, A; Villanueva, C, 1991) |
| "Pefloxacin was used to treat nosocomial pulmonary infections in 46 mechanically ventilated patients." | 1.27 | Pefloxacin in the treatment of nosocomial lower respiratory tract infections in intensive care patients. ( Fourrier, F; Gouin, F; Junginger, W; Martin, C; Prieur, BL, 1988) |
| "Pefloxacin was highly active against Staphylococcus aureus (39 strains; MIC90 1." | 1.27 | Activity of pefloxacin and thirteen other antimicrobial agents in vitro against isolates from hospital and genitourinary infections. ( Duerden, BI; Geary, I; Jones, BM; Lee, ME, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (37.50) | 18.7374 |
| 1990's | 10 (41.67) | 18.2507 |
| 2000's | 4 (16.67) | 29.6817 |
| 2010's | 1 (4.17) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mendonça, N | 1 |
| Leitão, J | 1 |
| Manageiro, V | 1 |
| Ferreira, E | 1 |
| Caniça, M | 1 |
| Quiroga, MP | 1 |
| Andres, P | 1 |
| Petroni, A | 1 |
| Soler Bistué, AJ | 1 |
| Guerriero, L | 1 |
| Vargas, LJ | 1 |
| Zorreguieta, A | 1 |
| Tokumoto, M | 1 |
| Quiroga, C | 1 |
| Tolmasky, ME | 1 |
| Galas, M | 1 |
| Centrón, D | 1 |
| Carrër, A | 1 |
| Poirel, L | 1 |
| Eraksoy, H | 1 |
| Cagatay, AA | 1 |
| Badur, S | 1 |
| Nordmann, P | 1 |
| Rajendran, R | 1 |
| Sreekumar, S | 2 |
| Sudhakar, A | 1 |
| Beam, TR | 1 |
| Cogollos, R | 1 |
| Alós, JI | 1 |
| Gómez-Garcés, JL | 1 |
| Fass, RJ | 1 |
| Barnishan, J | 1 |
| Ayers, LW | 1 |
| Cunha, BA | 1 |
| Qadri, SM | 1 |
| Ueno, Y | 1 |
| Walters, EA | 1 |
| Domenico, P | 1 |
| Campillo, B | 2 |
| Dupeyron, C | 2 |
| Richardet, JP | 2 |
| Mangeney, N | 1 |
| Leluan, G | 1 |
| Aparicio, JR | 1 |
| Such, J | 2 |
| Pascual, S | 1 |
| Arroyo, A | 1 |
| Plazas, J | 1 |
| Girona, E | 1 |
| Gutiérrez, A | 1 |
| de Vera, F | 1 |
| Palazón, JM | 1 |
| Carnicer, F | 1 |
| Pérez-Mateo, M | 1 |
| Cerra, FB | 1 |
| Maddaus, MA | 1 |
| Dunn, DL | 1 |
| Wells, CL | 1 |
| Konstantinides, NN | 1 |
| Lehmann, SL | 1 |
| Mann, HJ | 1 |
| Tomás, A | 1 |
| Soriano, G | 1 |
| Guarner, C | 1 |
| Teixidó, M | 1 |
| Méndez, C | 1 |
| Tena, F | 1 |
| Fábrega, E | 1 |
| Villanueva, C | 1 |
| Balanzó, J | 1 |
| Jia, CY | 1 |
| Corrado, ML | 1 |
| Roylance, PJ | 1 |
| Struble, WE | 1 |
| Lancaster, MS | 1 |
| Ulrich, C | 1 |
| Harinck-de Weerd, JE | 1 |
| Bakker, NC | 1 |
| Jacz, K | 1 |
| Doornbos, L | 1 |
| de Ridder, VA | 1 |
| Brettman, LR | 1 |
| Berardi-Grassias, LD | 1 |
| Roy, O | 1 |
| Scheife, RT | 1 |
| Cox, CE | 2 |
| McCabe, RE | 2 |
| Grad, C | 2 |
| Verbrugh, HA | 1 |
| Mintjes-de Groot, AJ | 1 |
| Andriesse, R | 1 |
| Hamersma, K | 1 |
| van Dijk, A | 1 |
| Martin, C | 1 |
| Gouin, F | 1 |
| Fourrier, F | 1 |
| Junginger, W | 1 |
| Prieur, BL | 1 |
| Jones, BM | 1 |
| Geary, I | 1 |
| Lee, ME | 1 |
| Duerden, BI | 1 |
| Tigaud, S | 1 |
| Marcatello, A | 1 |
| Gille, Y | 1 |
| Robert, D | 1 |
| Vincent, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Rifaximin Versus Norfloxacin in the Primary Prophylaxis of Spontaneous Bacterial Peritonitis[NCT04159870] | Phase 3 | 322 participants (Anticipated) | Interventional | 2019-11-05 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for norfloxacin and Cross Infection
| Article | Year |
|---|---|
Quinolone therapy in intensive care unit settings.
Topics: Administration, Oral; Aged; Ciprofloxacin; Clinical Protocols; Clinical Trials as Topic; Cross Infec | 1993 |
Nosocomial infection: risks associated with short-term and long-term inpatient care.
Topics: Aged; Anti-Bacterial Agents; Cross Infection; Humans; Length of Stay; Norfloxacin; Urinary Tract Inf | 1988 |
5 trials available for norfloxacin and Cross Infection
| Article | Year |
|---|---|
Selective gut decontamination reduces nosocomial infections and length of stay but not mortality or organ failure in surgical intensive care unit patients.
Topics: Adult; Bacteria; Candida; Critical Care; Cross Infection; Digestive System; Double-Blind Method; Hum | 1992 |
Review of the efficacy of oral norfloxacin in pyelonephritis and nosocomial urinary tract infection.
Topics: Administration, Oral; Antibody-Coated Bacteria Test, Urinary; Clinical Trials as Topic; Cross Infect | 1990 |
Selective decontamination of the digestive tract with norfloxacin in the prevention of ICU-acquired infections: a prospective randomized study.
Topics: Bacterial Infections; Cross Infection; Digestive System; Female; Gram-Negative Bacteria; Humans; Inc | 1989 |
Norfloxacin vs best parenteral therapy in treatment of moderate to serious, multiply-resistant, nosocomial urinary tract infections: a pharmacoeconomic analysis.
Topics: Anti-Bacterial Agents; Anti-Infective Agents, Urinary; Clinical Trials as Topic; Cost-Benefit Analys | 1988 |
Oral norfloxacin versus parenteral treatment of nosocomial urinary tract infection.
Topics: Adult; Aged; Aged, 80 and over; Aminoglycosides; Anti-Bacterial Agents; Clinical Trials as Topic; Cr | 1987 |
17 other studies available for norfloxacin and Cross Infection
| Article | Year |
|---|---|
Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.
Topics: Aged; Anti-Bacterial Agents; beta-Lactamases; Community-Acquired Infections; Cross Infection; Drug R | 2007 |
Complex class 1 integrons with diverse variable regions, including aac(6')-Ib-cr, and a novel allele, qnrB10, associated with ISCR1 in clinical enterobacterial isolates from Argentina.
Topics: Alleles; Amino Acid Sequence; Argentina; Bacterial Proteins; Base Sequence; beta-Lactamases; Cross I | 2007 |
Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey.
Topics: Bacterial Proteins; beta-Lactamases; Carbapenems; Cross Infection; Drug Resistance, Bacterial; Elect | 2008 |
Biodegradable tocopherol acetate as a drug carrier to prevent ureteral stent-associated infection.
Topics: Absorbable Implants; Anti-Infective Agents, Urinary; Bacterial Adhesion; Cross Infection; Drug Carri | 2011 |
[Evolution of fluoroquinolone sensitivity in Staphylococcus aureus isolated from hemocultures in a general hospital].
Topics: Bacteremia; Blood; Ciprofloxacin; Cross Infection; Drug Resistance, Microbial; Hospitals, General; H | 1993 |
Emergence of bacterial resistance to imipenem and ciprofloxacin in a university hospital.
Topics: Anti-Infective Agents; Bacteria; Ciprofloxacin; Cross Infection; Drug Resistance, Microbial; Drug Ut | 1995 |
Antibacterial activity of trovafloxacin against nosocomial Gram-positive and Gram-negative isolates.
Topics: Aminoglycosides; Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Cross Infection; Fluor | 1997 |
Epidemiology of severe hospital-acquired infections in patients with liver cirrhosis: effect of long-term administration of norfloxacin.
Topics: Aged; Anti-Infective Agents; Antibiotic Prophylaxis; Ascitic Fluid; Bacteremia; Cross Infection; Dru | 1998 |
Development of quinolone-resistant strains of Escherichia coli in stools of patients with cirrhosis undergoing norfloxacin prophylaxis: clinical consequences.
Topics: Aged; Anti-Infective Agents; Antibiotic Prophylaxis; Cross Infection; Drug Resistance, Microbial; Es | 1999 |
Epidemiology of hospital-acquired infections in cirrhotic patients: effect of carriage of methicillin-resistant Staphylococcus aureus and influence of previous antibiotic therapy and norfloxacin prophylaxis.
Topics: Anti-Infective Agents; Bacterial Infections; Carrier State; Cross Infection; Female; France; Humans; | 2001 |
[An analysis of hospital bacterial infections in cirrhotic patients undergoing selective intestinal decontamination].
Topics: Ascites; Bacterial Infections; Cross Infection; Decontamination; Female; Humans; Incidence; Intestin | 1991 |
[Drug resistance and floral distribution of Pseudomonas aeruginosa].
Topics: Amikacin; Burns; Ceftazidime; Cross Infection; Drug Resistance, Microbial; Female; Humans; Middle Ag | 1990 |
[Study of the sensitivity to pipemidic acid, pefloxacin and norfloxacin of 444 bacterial strains isolated at a general hospital].
Topics: Acinetobacter; Anti-Bacterial Agents; Cross Infection; Enterobacteriaceae; Humans; Microbial Sensiti | 1987 |
Postoperative prophylaxis with norfloxacin in patients requiring bladder catheters.
Topics: Adult; Aged; Aged, 80 and over; Alcaligenes; Bacteriuria; Catheters, Indwelling; Cross Infection; En | 1988 |
Pefloxacin in the treatment of nosocomial lower respiratory tract infections in intensive care patients.
Topics: Adolescent; Adult; Aged; Bronchopneumonia; Cross Infection; Female; Humans; Lung Abscess; Male; Midd | 1988 |
Activity of pefloxacin and thirteen other antimicrobial agents in vitro against isolates from hospital and genitourinary infections.
Topics: Anti-Bacterial Agents; Bacteria; Bacteria, Anaerobic; Cross Infection; Humans; Microbial Sensitivity | 1986 |
Pefloxacin: evolution of in vitro activity during 18 months of use in an intensive care unit.
Topics: Bacteria, Aerobic; Cross Infection; Humans; Intensive Care Units; Microbial Sensitivity Tests; Norfl | 1985 |